Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2010
    Down-regulation of GDNF Signaling in the Alpha-synuclein Model of PD: Implications for the Use of GDNF in Neuroprotective Therapy

    Objective/Rationale: 
    GDNF is currently the most effective, and best studied, survival factor acting on dopamine neurons (the neurons that die in Parkinson´s disease, PD). Infusion of GDNF into the...

  • Rapid Response Innovation Awards, 2010
    Identification of Small-molecule Stabilizers of DJ-1: Biophysical and Cellular Validation

    Objective/Rationale:
    The goal of our project is to develop an approach to treat PD by stabilizing wild-type dimeric DJ-1 with a small molecule. We hypothesize that this approach will lead to an...

  • Target Validation, 2010
    Does the Ubiquitin Ligase, Nedd4, Protect Against Alpha-Synucleinopathy?

    Objective/Rationale: 
    The cellular mechanisms that normally limit accumulation of alpha-synuclein are unclear. We have found that the enzyme, Nedd4, tags alpha-synuclein for destruction in lysosomes...

  • Rapid Response Innovation Awards, 2010
    Genetic Dissection of Parkinson's Disease Vulnerable Dopaminergic Neurons Population

    Objective/Rationale: 
    There is a clear heterogeneity in the susceptibility of dopamine neurons to Parkinson’s disease. Indeed, neurons of the substancia nigra ventral tier are specifically lost in...

  • MJFF Research Grant, 2010
    Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup

    Objective/Rationale: 
    Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association...

  • MJFF Research Grant, 2010
    Delayed Start Assessment of Progranulin in a Progressive Rodent Model of Parkinson’s Disease

    Promising Outcomes of Original Grant:
    In preliminary development work, we demonstrated the capacity of the protein progranulin to protect against disease development in several pre-clinical model...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.